Vi är en ny butik och allt är igång och skickas — om något skulle krångla, chatta live med en människa så löser vi det direkt.
Single Vial PeptidesVarje injektionsflaska skickas gratis inom USAGratis 3 ml bac water i kassan

Journal

Brand, compound, and research are three prices

Research vials on a bench. This note compares prices. It does not turn a research vial into a pen.

People search one name and get three prices. The brand pen, the compounded monthly program, and the research vial are not the same product, and the dollar on the ad is not always for the same amount of material. This note lines the prices up anyway. Each figure keeps the unit the seller actually used. A lower number is not a claim that one can stand in for another.

This shop does not sell the brand pen or the compounded prescription. The vials linked below are dry research material. Adults 21 and older. Not for people or animals. Not a pharmacy. If a doctor prescribed Mounjaro, Zepbound, Ozempic, or Wegovy, that purchase is the manufacturer's product, with the manufacturer's instructions. The rules for what this shop sells are on Research use. What is actually in the order is in What you are actually buying.

The short names are in What people mean by tirz, reta, and sema. The longer difference between a compounded prescription and a research vial is in Compounded and research. The reason Lilly and Novo use more than one brand for one ingredient is in Two names, one chemical. Salt form is in Lilly's pen is the base.

What each price is for

Brand. An FDA-approved finished medicine from Eli Lilly or Novo Nordisk. A prescription. A pen, a brand vial, or a pill, in a box the company defines as a month. Lilly and Novo set a list price, which is the wholesale number, and a lower self-pay price for people who pay cash. A savings card can cut a commercial copay further. Government programs are often excluded from that card. The pharmacy can still add its own charge.

Compound. A pharmacy-made preparation. Not FDA-approved. Not reviewed by the FDA for safety, effectiveness, or quality before it is sold. The public prices below are monthly program prices from clinics and telehealth sellers. Those ads usually do not print how many milligrams are in the month, so a compounded price cannot be turned into a per-milligram price from the advertisement alone.

Research. A dry vial from this shop, labeled with a milligram weight. One vial is the unit. It is not a month of medicine, not a pen, and not a compounded prescription. The specification on this shop is purity of at least 99 percent and a fill within 10 percent of the labeled weight. What those two numbers do and do not mean is in What 99% pure and a 10% fill actually mean. How to read the label is in How to read a research-vial label. Sale is to adults 21 and older. The material is not for people or animals. Free USA shipping on every order. The note is on USA shipping. The per-milligram figures below use the vial price alone. The price at the door is the vial price.

Tirzepatide

Mounjaro and Zepbound are both Lilly tirzepatide. Same weekly strengths on the box, 2.5 mg through 15 mg. Different brands, different price sheets. The approved labels are Mounjaro and Zepbound. This shop's sizes are on Tirz. The one-vial note is One vial of tirz. None of those vials is either brand. Lilly's Zepbound price page puts the list price at $499 to $1,086.37 per fill. Lilly says that list price is the wholesale acquisition cost, from AnalySource as of January 1, 2026, and that a monthly supply is 28 days. The same page offers Zepbound as a 4-count single-dose vial, 0.5 mL each, and as a KwikPen, 2.4 mL with 0.6 mL per dose. That is four doses in the month. The direct-to-patient prices on that page, in strength order from 2.5 mg through 15 mg, are $299, $399, $499, $699, $699, and $699. With commercial insurance that covers the pens, Lilly's card can bring a one-month or three-month fill down to $25. Government beneficiaries are excluded.

Lilly's Mounjaro price page puts the list price at $1,112.16 per fill, also from the January 1, 2026 wholesale figure, and says one fill is four pens. LillyDirect's Mounjaro page lists a self-pay price starting at $499 a month for every strength from 2.5 mg through 15 mg, and says additional taxes and fees may apply. Mounjaro's savings page says an eligible commercially insured person whose plan covers the drug may pay as little as $25, and a person with commercial insurance that does not cover it may pay as low as $499 for a one-month fill of the single-dose pen. Government beneficiaries are excluded from that card.

A separate price tracker, GLP Chart, checked October 5, 2026, prints a different LillyDirect number for the higher Zepbound strengths: $449 a month from 7.5 mg through 15 mg if the refill is inside 45 days. That is GLP Chart's reading of seller pages, not the ladder on Lilly's own price page. Both are linked. The manufacturer's page is the one quoted above. GLP Chart, October 5, 2026.

Compounded tirzepatide is sold as a month, not as a labeled milligram count, in the sources opened for this note. It is not an FDA-approved drug. The record after the shortages ended is in Compounded semaglutide and tirzepatide after the shortage. Who is offering it, and who has drawn an FDA letter, is in Who is selling, and who got a letter. WWD, on October 21, 2025, citing the analytics firm Guidepoint Qsight, put the average compounded price at aesthetics practices at $485 a month for tirzepatide. WWD spelled the drug "tirzeptatide" in that sentence. The same paragraph put compounded semaglutide at $350 a month. WWD, October 21, 2025. GLP Chart's October 5, 2026 check of five telehealth sellers put month-to-month compounded tirzepatide at $149 with auto-refill at one seller, $299 at another, and $348 or $349 at the rest. GLP Chart called $348 the middle of that set. Those sellers are not this shop. The pages do not state the milligrams in the month. Guidepoint's average is from 2025 aesthetics practices. GLP Chart's range is from 2026 telehealth menus. They are two different samples, and neither is a census of every compounder.

This shop's tirzepatide is a research vial, not Mounjaro and not Zepbound. The catalog prices for one vial are:

Multi-vial packs on those pages can change the price per vial. The figures above are the single-vial price.

Semaglutide

Ozempic, Rybelsus, and Wegovy are all Novo semaglutide. They are not the same box. This shop's vial is not any of them. The sizes page is Sema. The one-vial note is One vial of sema. NovoCare's Wegovy page, read here on October 12, 2026, prints a list price of $1,349.02 per package for the pill, the pen, and the HD pen. Self-pay on that page is lower, and it depends on the form. The pill is $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg. A pill month is one bottle of 30 tablets. The pen is $349 a month at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, and $399 a month for the 7.2 mg HD pen. New patients pay $199 for each of the first two monthly fills of the 0.25 mg and 0.5 mg pens, through December 31, 2026. A pen month is one box of four pens. Commercial insurance can bring it to $25, subject to a maximum savings of $100 a month. Government beneficiaries are excluded. NovoCare, Wegovy.

Novo's Ozempic price guide, marked May 2026, sets the pill at $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg. A pill month is 30 tablets. The pen is $349 a month for 0.25 mg, 0.5 mg, or 1 mg, and $499 a month for 2 mg, after a new-patient price of $199 for each of the first two monthly fills of 0.25 mg and 0.5 mg through December 31, 2026. An Ozempic pen month is one box of one pen, not four pens. The same commercial-card terms apply: as little as $25, maximum savings $100 a month, government beneficiaries excluded. Ozempic price guide, NovoCare.

On February 24, 2026 Novo said that on January 1, 2027 the list price of Wegovy, Ozempic, and Rybelsus goes to $675 a month. Novo called that about a 50 percent cut for Wegovy and about a 35 percent cut for Ozempic, and said the self-pay prices were not part of the cut. Novo Nordisk, February 24, 2026. Half of the $1,349.02 Wegovy list on the NovoCare page is $674.51, which is the "about 50 percent" in that release. The release does not print today's Ozempic list price, only the percentage and the 2027 number. Medicare's negotiated 2027 price for the Ozempic, Rybelsus, and Wegovy line is a separate figure, written up in Two names, one chemical.

Compounded semaglutide, same two sources as the tirzepatide compounds. Guidepoint's average, via WWD, was $350 a month at aesthetics practices. GLP Chart's October 5, 2026 month-to-month sample of six telehealth sellers ran from $149 with auto-refill to $348, and GLP Chart called $293 the middle. Again, those pages price a month. They do not print the milligrams.

Semaglutide is sold here as single research vials. Buy one or as many as you like. It is not Ozempic, not Wegovy, and not a compounded month. Sema 5mg is $35, which is $7.00 per labeled milligram. Twelve of those vials are $350. Twelve times 5 mg is 60 mg, and $350 divided by 60 mg is $5.83 per labeled milligram.

Dollars per labeled milligram

This section is division. It is not a dose, and it is not a statement that the products are interchangeable. A smaller dollar figure on a research vial does not turn that vial into the pen next to it.

A Zepbound month is four weekly doses. A 15 mg self-pay fill at $699 therefore holds 60 mg of labeled tirzepatide. $699 divided by 60 is $11.65 per labeled milligram. A 2.5 mg fill at $299 holds 10 mg. That is $29.90 per labeled milligram. The list price is a range, $499 to $1,086.37 per fill, and Lilly's page does not assign each end of that range to a strength in the sentence quoted here, so this note does not divide the list price by a guessed strength.

A Mounjaro fill is four pens at $1,112.16 list, or starting at $499 self-pay. At the 15 mg strength that fill holds 60 mg. List price divided by 60 is $18.54 per labeled milligram. The $499 starting self-pay divided by 60 is $8.32. At the 2.5 mg strength the same dollar prices sit on 10 mg, which is $111.22 list and $49.90 at the starting self-pay. The wholesale sticker does not fall when the strength does. The dollars per labeled milligram do.

A Wegovy pen month is four pens. The 2.4 mg box holds 9.6 mg. Self-pay of $349 divided by 9.6 is $36.35 per labeled milligram. The $1,349.02 list divided by 9.6 is $140.52. The 7.2 mg HD box holds 28.8 mg. Self-pay of $399 divided by 28.8 is $13.85. The same $1,349.02 list divided by 28.8 is $46.84. A 0.25 mg box holds 1 mg, so the $349 self-pay, or the $199 introductory price, is the price of that 1 mg. The pill is left out of this division. A bottle of daily tablets is not an injectable vial, and a milligram of an oral tablet is not a milligram in a pen.

An Ozempic month is one pen. Novo's price guide states the dose and the box. It does not state, on that page, the total milligrams inside the pen. This note does not invent that total in order to force a per-milligram line.

Set beside those boxes, this shop's labeled weights. Read these as two stickers, not as a swap. The research vial is not a month of the brand drug:

Those pairs share a milligram count on a label. They do not share an approval, a manufacturer, a pharmacy record, or a finished-dose form. The research vial is dry material with a weight on it. The pen is a finished medicine with a month written on the box.

Retatrutide has a research price and no brand price

Lilly's September 2026 page on retatrutide says it is not approved, that a public price comes after trials and regulatory review, and that the company intends to price it, in Lilly's words, "to reflect the overall value to the healthcare system." The same page says anything sold to consumers outside Lilly's trials is not Lilly's product. Lilly, September 2026. There is no Mounjaro-style list price to put in the brand column. Guessed launch prices on clinic blogs are not Lilly's price, and they are not used here.

There is also no lawful compounded column. The FDA has said retatrutide cannot be used in compounding. FDA, concerns with unapproved GLP-1 drugs. That record is in Retatrutide is still not approved. A monthly "reta" advertisement is not a third official price.

The prices below are research vials on Reta. They are not Lilly's drug. The one-vial note is One vial of reta.

The research prices on this shop are:

What the lower number is not

The research vial is the cheap line on a per-milligram basis in the arithmetic above. That is a fact about the sticker and the labeled weight. It is not a finding that the vial is the brand drug, the compounded drug, or a month of either. "Research grade" is not an FDA tier. A compounded month at $149 or $485 is not a Zepbound fill, and a Zepbound fill at $299 is not a research vial. Prices move. Lilly, Novo, and the clinics can change a self-pay offer without changing the list price. The catalog prices in this note are this shop's prices on the day the page was written.

The other names in the shop, BPC-157, TB-500, Wolverine, GHK-Cu, KPV, GLOW, KLOW, MOTS-c, NAD+, CJC-1295 with ipamorelin, sermorelin, and tesamorelin, do not have a current Zepbound-style pen to set beside the vial. Their prices are on every peptide page. This comparison is the one place a brand price, a compound price, and a research price all exist in public, and for retatrutide the brand price and the compound price do not.

Same warning as the top of the page. A cheaper labeled milligram here is a research vial. It is not the pen, and it is not the compounded month. Questions about the shop are on the FAQ. The sale terms are on Research use.

Sources

Brand prices and labels:

Compound prices, and the FDA page on this class:

Research prices are this shop's catalog, on Tirz, Sema, and Reta.

Research material. Adults 21 and older. Not for people or animals. Not a pharmacy. Not medical advice. Not a Lilly or Novo product.

Injektionsflaskor för forskning. 21 eller äldre. Inte för människor eller djur. Inte medicinsk rådgivning.